Evidence map›Paper›PMID 19541912›Full record

ArticleGenome research2009

Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing.

J Douglas Freeman, René L Warren, John R Webb, Brad H Nelson, Robert A Holt

Registry-linked trialOpen access · bronzeAbstract readValidation Study
In one paragraph

Article in Genome research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04273061 (Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention), which is not on this map. Cited by 234 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04273061 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2020 to 2027Enrolled200ConditionsBreast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary CancerArmsAtezolizumab
3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 1 synthesis or guideline pooled it, 408 citations in OpenAlex.

  1. Pooled it
  2. Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. General and individualized changes in T cell immunity during aging.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Review
  18. Article
  19. Article
  20. Review

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J Douglas FreemanMichael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
René L Warren
John R Webb
Brad H Nelson
Robert A Holt
BC Cancer Agency · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell receptor (TCR) genomic loci undergo somatic V(D)J recombination, plus the addition/subtraction of nontemplated bases at recombination junctions, in order to generate the repertoire of structurally diverse T cells necessary for antigen recognition. TCR beta subunits can be unambiguously identified by their hypervariable CDR3 (Complement Determining Region 3) sequence. This is the site of V(D)J recombination encoding the principal site of antigen contact. The complexity and dynamics of the T-cell repertoire remain unknown because the potential repertoire size has made conventional sequence analysis intractable. Here, we use 5'-RACE, Illumina sequencing, and a novel short read assembly strategy to sample CDR3(beta) diversity in human T lymphocytes from peripheral blood. Assembly of 40.5 million short reads identified 33,664 distinct TCR(beta) clonotypes and provides precise measurements of CDR3(beta) length diversity, usage of nontemplated bases, sequence convergence, and preferences for TRBV (T-cell receptor beta variable gene) and TRBJ (T-cell receptor beta joining gene) gene usage and pairing. CDR3 length between conserved residues of TRBV and TRBJ ranged from 21 to 81 nucleotides (nt). TRBV gene usage ranged from 0.01% for TRBV17 to 24.6% for TRBV20-1. TRBJ gene usage ranged from 1.6% for TRBJ2-6 to 17.2% for TRBJ2-1. We identified 1573 examples of convergence where the same amino acid translation was specified by distinct CDR3(beta) nucleotide sequences. Direct sequence-based immunoprofiling will likely prove to be a useful tool for understanding repertoire dynamics in response to immune challenge, without a priori knowledge of antigen.

Indexed as

Genes, T-Cell Receptor betaAlgorithmsAntibody DiversityCloning, MolecularGene Expression ProfilingGenetic VariationHumansImmunoglobulin Variable RegionModels, BiologicalReceptors, Antigen, T-Cell, alpha-betaSequence Analysis, DNAVDJ RecombinasesImmunoglobulin Variable RegionReceptors, Antigen, T-Cell, alpha-betaVDJ Recombinases

Identifiers

PMID19541912
PMCPMC2765271
OpenAlexW1978391087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.